Arvinas, Inc. ARVN
We take great care to ensure that the data presented and summarized in this overview for ARVINAS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ARVN
View all-
Eco R1 Capital, LLC San Francisco, CA6.73MShares$220 Million7.92% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.3MShares$206 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.49MShares$180 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.37MShares$143 Million0.02% of portfolio
-
Rtw Investments, LP New York, NY3.3MShares$108 Million2.18% of portfolio
-
Avidity Partners Management LP Dallas, TX2.99MShares$97.6 Million4.76% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.61MShares$85.5 Million4.05% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.39MShares$78.1 Million1.55% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.28MShares$74.5 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY1.7MShares$55.6 Million0.01% of portfolio
Latest Institutional Activity in ARVN
Top Purchases
Top Sells
About ARVN
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Insider Transactions at ARVN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 18
2024
|
Noah Berkowitz Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
63,452
+50.0%
|
-
|
|
Feb 23
2024
|
Sean A Cassidy Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,702
-0.93%
|
$79,994
$47.05 P/Share
|
|
Feb 23
2024
|
John G Houston President and CEO |
SELL
Open market or private sale
|
Direct |
5,196
-0.5%
|
$244,212
$47.05 P/Share
|
|
Feb 23
2024
|
John G Houston President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
124,450
+10.67%
|
-
|
|
Feb 23
2024
|
David K Loomis Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,750
+40.35%
|
-
|
|
Feb 23
2024
|
Ian Taylor Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,701
-1.14%
|
$79,947
$47.05 P/Share
|
|
Feb 23
2024
|
Ian Taylor Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,250
+20.83%
|
-
|
|
Feb 23
2024
|
Ronald Peck Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,699
-2.45%
|
$79,853
$47.05 P/Share
|
|
Feb 23
2024
|
Ronald Peck Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,250
+36.19%
|
-
|
|
Jan 04
2024
|
Ian Taylor Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,252
+6.98%
|
$132,032
$16.0 P/Share
|
|
Aug 11
2023
|
Ronald Peck Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,324
-4.23%
|
$31,776
$24.39 P/Share
|
|
Aug 11
2023
|
Ronald Peck Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,010
+11.36%
|
-
|
|
Jun 15
2023
|
Sunil Agarwal Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,242
+50.0%
|
-
|
|
Jun 15
2023
|
Linda Bain Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+50.0%
|
-
|
|
Jun 15
2023
|
Everett Cunningham Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+50.0%
|
-
|
|
Jun 15
2023
|
Wendy L Dixon Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+31.12%
|
-
|
|
Jun 15
2023
|
Edward Moore Kennedy Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+19.05%
|
-
|
|
Jun 15
2023
|
Briggs Morrison Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+14.6%
|
-
|
|
Jun 15
2023
|
Leslie V Norwalk Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+50.0%
|
-
|
|
Jun 15
2023
|
Alsup Laurie Smaldone Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,121
+50.0%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 313K shares |
|---|---|
| Exercise of conversion of derivative security | 12.3K shares |
| Open market or private sale | 11.6K shares |
|---|